Ocular surface wound healing

Ocular surface wound healing" is not a single molecule or receptor but rather a **complex biological process** involving multiple cell types (such as epithelial cells, limbal stem cells), signaling molecules (cytokines and growth factors like TGF-beta isoforms, EGF, bFGF), enzymes (notably matrix metalloproteinases such as MMP2, MMP9, and MMP13), and immune mediators[1][3][5][6]. The process includes several overlapping phases—latent/lag phase (cellular remodeling and preparation for repair), migration of epithelial cells to cover the defect, proliferation to restore tissue thickness, differentiation of new cells into mature corneal epithelium, and reformation of cell junctions to re-establish barrier function[1][3]. Key molecular pathways include cytokine signaling (e.g., IL-1/TGF-beta axis) that regulate extracellular matrix turnover via metalloproteinases; imbalances in these can lead to impaired or excessive scarring[3][5]. Immune responses also play a role in modulating inflammation during the repair process[2]. Because "ocular surface wound healing" refers to an entire physiological cascade rather than a discrete molecular target such as a receptor or enzyme—and because it encompasses many different molecules—it is **not considered a therapeutic target itself**, but rather an area where multiple targets may be identified for intervention. Therefore: **This entry is incorrect as a canonical drug target.** It should be replaced with specific molecular entities involved in ocular surface/corneal wound healing processes—such as "Transforming growth factor beta 3", "Matrix metalloproteinase 9", or "Epidermal growth factor receptor"—for structured data on drug targeting. If you need information about individual molecules within this pathway that are considered therapeutic targets for ocular/corneal wound healing interventions (e.g., TGF-beta isoforms or specific MMPs), please specify which one.

Other names

Corneal wound healingCorneal epithelial wound healingOcular surface repair